Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials
Background. To investigate the efficacy and safety of guselkumab in the treatment of moderate-to-severe plaque psoriasis. Methods. A systematic review was undertaken to identify double-blind randomized controlled trials (RCTs). PubMed, Web of Science, Cochrane Library, EMBASE, and Google Scholar dat...
Main Authors: | Jing Yang, Zongming Wang, Xilin Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2020/4975628 |
Similar Items
-
Guselkumab in the treatment of patients with plaque psoriasis of moderate and severe severity: Efficacy and safety of interleukin-23 blockade
by: V. V. Chikin
Published: (2020-01-01) -
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021-01-01) -
Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
by: Marco Galluzzo, et al.
Published: (2020-07-01) -
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Fan Bai, et al.
Published: (2019-01-01) -
Evaluating guselkumab: an anti-IL-23 antibody for the treatment of plaque psoriasis
by: Yang EJ, et al.
Published: (2019-06-01)